| Patient | Ernest Hemingway |
|---|---|
| Date of birth | 1970-07-21 |
| Identifiers | MRN HR-ET003-SYN; SSN (made up) 000-03-7419 |
| Document date | 2026-06-08 |
| Author | Walter Brandt-Ochoa, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Fourteen-week review: phlebotomy, stopping alcohol, mood and blood pressure. [S]
Mr. Hemingway returns fourteen weeks after intake and four weeks after the sick visit; the hand healed completely after the antibiotics. He came down by one drink a week as planned and has had no alcohol for three weeks. He had two nights of poor sleep after the last drink and no tremor, sweating or confusion. He keeps taking naltrexone and says the evening craving is weaker. He has had ten phlebotomies, with one skipped in the week of the hand infection, and the eleventh is planned after today's blood tests. Sertraline 100 mg causes no side effects; his mood is better and his PHQ-9 is 8, but no PHQ-9 had been done since the six-week visit. Home blood pressure averages 134/84. Headaches are down to one or two a week. His guns remain at the club. The echocardiogram has still not been done: the order went to an imaging center that never contacted him. [S]
| Element | Detail |
|---|---|
| Alcohol | None for three weeks after a gradual reduction; AUDIT-C 3 for the past month |
| Withdrawal | Two nights of poor sleep; no tremor or confusion |
| Phlebotomy | Ten sessions (one skipped); the eleventh today |
| Mood | PHQ-9 8; item 9 scored 0 |
| Home blood pressure | Average 134/84 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | More energy; weight down 3 kg since intake |
| Integumentary | Negative | Hand healed |
| Neurological | Positive | Headaches once or twice a week; no tremor |
| Psychiatric | Positive | Mood better; sleeping six hours; no thoughts of suicide or wishes to be dead since the last visit |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naltrexone 50 mg oral tablet, one tablet daily, to reduce heavy drinking | One tablet daily | Oral route | 2026-03-02 | active | S |
| Thiamine 100 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-08-31 | completed | S |
| Sertraline 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-04-13 | completed | S |
| Sertraline 100 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-04-13 | active | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-06-08 | completed | S |
| Amlodipine 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-06-08 | active | S |
| Cephalexin 500 mg oral capsule, one capsule four times daily for seven days | One capsule four times daily for seven days | Oral route | 2026-05-11 to 2026-05-18 | completed | S |
| Doxycycline hyclate 100 mg oral capsule, one capsule twice daily for seven days, with a full glass of water, sitting upright | One capsule twice daily for seven days | Oral route | 2026-05-11 to 2026-05-18 | completed | S |
| Acetaminophen 500 mg oral tablet, one or two tablets every 6 hours as needed for pain, no more than 2,000 mg a day while he is drinking | One or two tablets every 6 hours as needed, up to 2,000 mg a day | Oral route | 2026-05-11 to 2026-05-18 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-08 | Body height | 183 | cm | S |
| 2026-06-08 | Body weight | 94.6 | kg | S |
| 2026-06-08 | Body mass index (BMI) [Ratio] | 28.2 | kg/m2 | S |
| 2026-06-08 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2026-06-08 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-06-08 | Heart rate | 76 | /min | S |
| 2026-06-08 | Respiratory rate | 14 | /min | S |
| 2026-06-08 | Body temperature | 36.7 | Cel | S |
| 2026-06-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-08 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-06-08 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 96 | fL | 80-100 fL | Normal | S |
| 2026-06-08 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 32 | U/L | 10-40 U/L | Normal | S |
| 2026-06-08 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 36 | U/L | 7-55 U/L | Normal | S |
| 2026-06-08 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 58 | U/L | 8-61 U/L | Normal | S |
| 2026-06-08 | Ferritin [Mass/volume] in Serum or Plasma | 620 | ng/mL | 24-336 ng/mL | High | S |
| 2026-06-08 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-06-08 | Total score [AUDIT-C] | 3 | {score} | S |
Vital signs recorded on 2026-06-08; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 134/84, pulse 76; weight 94.6 kg |
| Skin | Right hand healed without redness |
| Abdomen | Liver edge not palpable; no spleen felt |
| Neurological | No tremor |
| Psychiatric | Brighter and more talkative |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Alcohol use disorder, severe; heavy daily drinking for most of his adult life; synthetic modern episode linked to his documented heavy drinking | active | confirmed | F10.20 | S — Synthetic modern coding of DSM-5-TR severe alcohol use disorder (seven criteria); person-first language; not a claim about his real diagnosis. |
| Raised transferrin saturation and ferritin found on routine intake tests, cause not yet known (heavy drinking, liver disease or iron overload) | resolved | confirmed | R79.0 | S — Synthetic presenting finding; superseded when HFE testing gave the diagnosis. |
| Hereditary hemochromatosis, HFE C282Y homozygous, with iron overload (ferritin over 1,000 ng/mL) and no advanced liver fibrosis on imaging | active | confirmed | E83.110 | S — Synthetic modern diagnosis. Whether he had hemochromatosis is disputed (CLM-0013); the modern diagnosis is not offered as proof of it. |
| Major depressive disorder, single episode, moderate; Mood Disorder Questionnaire negative and no history of mania or hypomania | active | confirmed | F32.1 | S — Synthetic modern diagnosis; not a claim about his real mood. The roster's bipolar disorder lead is disputed (CLM-0014) and is not used. |
| Essential hypertension, stage 2, with heavy drinking contributing | active | confirmed | I10 | S — Synthetic modern diagnosis confirmed by home readings. |
| Post-concussion symptoms (headaches, slowed thinking and forgetfulness) after repeated head injuries, most recently a concussion with a skull fracture a year ago; chronic traumatic encephalopathy is not diagnosed | active | confirmed | F07.81 | S — Synthetic modern diagnosis anchored to his documented head injuries; alcohol and depression also affect the symptoms. |
| Prediabetes (HbA1c 6.1%) | active | confirmed | R73.03 | S — Synthetic finding on diabetes screening; iron overload and alcohol both raise the risk of diabetes. |
| Fishhook puncture wound of the right hand with early cellulitis after saltwater exposure, in a man with iron overload; treated with antibiotics covering Vibrio; resolved | resolved | confirmed | L03.113 | S — Synthetic acute illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hemoglobin before each phlebotomy (hold if under 12.0 g/dL) | Before every session; full blood count at visits | Completed today | Hemoglobin 13.6 g/dL, MCV 96 fL; no session held for anemia |
| Laboratory | Serum ferritin during induction phlebotomy | At diagnosis, then about every 10 to 12 phlebotomies; target 50 to 100 ng/mL | Completed today | Ferritin 620 ng/mL after ten sessions |
| Medication safety | Weekly phlebotomy of 500 mL | Weekly during induction | Completed today | Ten sessions; one held in the week of the hand infection; the eleventh today |
| Imaging | Liver cancer surveillance | Every six months only with cirrhosis or advanced fibrosis | Not indicated | No advanced fibrosis on MRI |
| Self-management | Diet: no iron or vitamin C supplements, no raw shellfish | Every visit | Completed today | No supplements; no raw shellfish |
| Laboratory | Liver tests on naltrexone | Baseline, about one month, then every three to six months | Completed today | AST 32, ALT 36 and GGT 58 U/L; normal |
| Survey | Drinking quantity and goal (AUDIT-C, drinking diary) | Every visit | Completed today | AUDIT-C 3 for the past month; none for three weeks |
| Medication safety | Opioid use and pain plan on naltrexone | Every visit | Completed today | No opioids; none needed for the hand |
| Examination | Alcohol withdrawal risk and symptoms when cutting down or stopping | When stopping | Completed today | Gradual reduction; two nights of poor sleep only |
| Medication safety | Thiamine | Daily while drinking heavily | Completed today | Taking thiamine; review at six months |
| Survey | Depression (PHQ-9) | At least monthly during acute treatment | Deferred | PHQ-9 8 today, eight weeks after the last score, longer than the monthly check advised; the sick visit did not repeat it. No harm resulted: his weekly therapist saw steady improvement and today's score is lower. Corrective action: PHQ-9 monthly by the behavioral health clinician, recorded in the chart |
| Medication safety | Sertraline adherence and side effects | Two weeks after starting or changing the dose, then each visit | Completed today | 100 mg; reviewed by the behavioral health clinician two weeks after the increase; no side effects |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, firearm storage and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | C-SSRS screen negative since the last visit; firearms remain off-site by his choice |
| Self-management | Psychotherapy (CBT) | Weekly | Completed today | Attending weekly |
| Examination | Blood pressure, home readings, weight and cardiac auscultation | Every visit | Completed today | 134/84 in clinic; home average 134/84; weight 94.6 kg; amlodipine increased |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension | Deferred | Not done fourteen weeks after it was ordered: the order went to an outside imaging center that never contacted him. No harm so far: no symptoms, no murmur, and the ECG showed only borderline voltage. Corrective action: rebooked through the clinic's scheduler, with the result checked at the six-month visit |
| Examination | Post-concussion symptoms (headache frequency, sleep, concentration) | Every visit | Completed today | Headaches once or twice a week |
Goal progress:
Guideline basis: Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases (2011); ACG Clinical Guideline: Hereditary Hemochromatosis (2019); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); VA/DoD Clinical Practice Guideline for the Management and Rehabilitation of Post-Acute Mild Traumatic Brain Injury (2021); CMID: Clinical Monitoring Intelligence Database, hypertension and depression, bipolar, and mood disorders monographs (2026)
Follow-up: Weekly phlebotomy. Monthly PHQ-9 with the behavioral health clinician. Echocardiogram before the six-month visit. Preventive visit in seven weeks. Six-month review in twelve weeks with blood count, iron studies, liver tests, HbA1c, lipids, PHQ-9, AUDIT-C and MoCA. Next scheduled visit 2026-07-27: periodic adult preventive visit. [S]